Practical Considerations and Radiation Safety in Radioimmunotherapy with Yttrium 90 Ibritumomab Tiuxetan (Zevalin)

Leo I. Gordon*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

90Y ibritumomab tiuxetan (Zevalin; Biogen Idec Inc, Cambridge, MA), the first radioimmunotherapeutic agent approved by the US Food and Drug Administration, is a promising treatment option in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with rituximab-refractory follicular non-Hodgkin's lymphoma. The ibritumomab tiuxetan regimen is administered on an outpatient basis over approximately 1 week and with the simplicity of weight-based dosing (ie, calculation of whole body clearance is unnecessary). Other than acrylic shielding, only universal precautions are required to administer 90Y ibritumomab tiuxetan, and patient isolation is unnecessary. This treatment regimen requires a coordinated multidisciplinary approach. Oncologists play a leading role in selecting patients for 90Y ibritumomab tiuxetan therapy and in prescribing and overseeing the treatment.

Original languageEnglish (US)
Pages (from-to)23-28
Number of pages6
JournalSeminars in Oncology
Volume30
Issue number6 SUPPL. 17
DOIs
StatePublished - Dec 2003

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Practical Considerations and Radiation Safety in Radioimmunotherapy with Yttrium 90 Ibritumomab Tiuxetan (Zevalin)'. Together they form a unique fingerprint.

Cite this